This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by El-Hizawi, S. Articles by Albor, A. Search for Related Content PubMed PubMed Citation Articles by El-Hizawi, S. Articles by Albor, A.

Induction of Gene Amplification as a Gain-of-Function Phenotype of Mutant p53 Proteins¹

Department of Dermatology, Oregon Health and Science University, Portland Oregon 97201

Gene amplification accompanies tumor progression and is involved in the development of drug resistance. Previously, we reported (A. Albor et al., Cancer Res. 58: 2091–2094, 1998) that mutant p53 proteins conserve the capacity to interact with and activate topoisomerase I, and that this could be a mechanism for induction of genomic instability by mutant p53 proteins. To test this hypothesis, the effect of exogenous mutant p53 protein expression on genomic instability in human p53-/- Saos-2 cells was measured by the frequency of formation of N-(phosphoacetyl)-L-aspartate (PALA)-resistant (PALA^R) colonies, mediated by gene amplification. Interaction of exogenous mutant p53 and topoisomerase I was confirmed by immunoprecipitation. Growth under continuous expression of mutant p53 proteins for 16–17 population doublings increased the frequency of appearance of PALA^R colonies after subsequent exposure to PALA. Subtoxic concentrations of camptothecin (which stabilizes topoisomerase I cleavage complexes, mediating nonhomologous recombination) produced a dose-dependent increase in PALA^R colonies, and combining expression of mutant p53 with exposure to camptothecin produced a greater than additive increase in PALA^R colony formation. These results indicate that mutant p53 proteins promote gene amplification independently of their capacity to inactivate the wild-type p53 protein, and suggest that this effect is dependent on interaction of mutant p53 with topoisomerase I. Additional studies are needed to assess the potential of targeting mutant p53 interaction with topoisomerase I for the reduction of drug resistance development during chemotherapy.

This article has been cited by other articles:

				A. Restle, M. Farber, C. Baumann, M. Bohringer, K. H. Scheidtmann, C. Muller-Tidow, and L. Wiesmuller Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants Nucleic Acids Res., September 1, 2008; 36(16): 5362 - 5375. [Abstract] [Full Text] [PDF]

				F. Vikhanskaya, M. K. Lee, M. Mazzoletti, M. Broggini, and K. Sabapathy Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53 Nucleic Acids Res., March 19, 2007; 35(6): 2093 - 2104. [Abstract] [Full Text] [PDF]

				Y. Buganim, E. Kalo, R. Brosh, H. Besserglick, I. Nachmany, Y. Rais, P. Stambolsky, X. Tang, M. Milyavsky, I. Shats, et al. Mutant p53 Protects Cells from 12-O-Tetradecanoylphorbol-13-Acetate-Induced Death by Attenuating Activating Transcription Factor 3 Induction. Cancer Res., November 15, 2006; 66(22): 10750 - 10759. [Abstract] [Full Text] [PDF]

				C. Baumann, G. S. Boehden, A. Burkle, and L. Wiesmuller Poly(ADP-RIBOSE) polymerase-1 (Parp-1) antagonizes topoisomerase I-dependent recombination stimulation by P53 Nucleic Acids Res., February 9, 2006; 34(3): 1036 - 1049. [Abstract] [Full Text] [PDF]

				T. Göhler, S. Jäger, G. Warnecke, H. Yasuda, E. Kim, and W. Deppert Mutant p53 proteins bind DNA in a DNA structure-selective mode Nucleic Acids Res., February 18, 2005; 33(3): 1087 - 1100. [Abstract] [Full Text] [PDF]

				G. S. Boehden, A. Restle, R. Marschalek, C. Stocking, and L. Wiesmuller Recombination at chromosomal sequences involved in leukaemogenic rearrangements is differentially regulated by p53 Carcinogenesis, August 1, 2004; 25(8): 1305 - 1313. [Abstract] [Full Text] [PDF]

				S. Pospisilova, C. Siligan, J. Ban, G. Jug, and H. Kovar Constitutive and DNA Damage Inducible Activation of pig3 and MDM2 Genes by Tumor-Derived p53 Mutant C277Y Mol. Cancer Res., May 1, 2004; 2(5): 296 - 304. [Abstract] [Full Text] [PDF]

				B. Hann and A. Balmain Replication of an E1B 55-Kilodalton Protein-Deficient Adenovirus (ONYX-015) Is Restored by Gain-of-Function Rather than Loss-of-Function p53 Mutants J. Virol., November 1, 2003; 77(21): 11588 - 11595. [Abstract] [Full Text] [PDF]

				Y. Okada, E. E. Hurwitz, J. M. Esposito, M. A. Brower, C. L. Nutt, and D. N. Louis Selection Pressures of TP53 Mutation and Microenvironmental Location Influence Epidermal Growth Factor Receptor Gene Amplification in Human Glioblastomas Cancer Res., January 15, 2003; 63(2): 413 - 416. [Abstract] [Full Text] [PDF]

				H. Stephan, F. Grosse, and K. Soe Human topoisomerase I cleavage complexes are repaired by a p53-stimulated recombination-like reaction in vitro Nucleic Acids Res., December 1, 2002; 30(23): 5087 - 5093. [Abstract] [Full Text] [PDF]